Harnessing Sphingolipid Biology for Targeted Degradation of Soluble & Membrane Proteins

• Building on fundamental discoveries in sphingolipid biology, Transcera develop a new modality for extracellular protein degradation that harness native ceramide trafficking pathways
• Transcera’s degraders work across multiple cell types in tissues throughout the body and have extended half-life for durable target depletion,
• Transcera discovered new degraders for immune-mediated disease and is advancing towards a clinical candidate

Speakers:

Justin Wolfe

Co-Founder & Chief Scientific Officer

Transcera Inc.